In fact, cAMP/PKA/CREB enhancers, such as rolipram and forskolin (PKA activators), have been proposed as useful to memory impairment [29] and also for AD treatment since one of the main protagonists in this neurodegenerative disorder, amyloid-beta (Aβ), also inhibits the PKA/CREB pathways and long-term potentiation [30]. This evidence concerns the gene CREB1 and Alzheimer disease.